579 related articles for article (PubMed ID: 28373570)
1. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.
Echigoya Y; Nakamura A; Nagata T; Urasawa N; Lim KRQ; Trieu N; Panesar D; Kuraoka M; Moulton HM; Saito T; Aoki Y; Iversen P; Sazani P; Kole R; Maruyama R; Partridge T; Takeda S; Yokota T
Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4213-4218. PubMed ID: 28373570
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy.
Yokota T; Hoffman E; Takeda S
Methods Mol Biol; 2011; 709():299-312. PubMed ID: 21194037
[TBL] [Abstract][Full Text] [Related]
6. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
[TBL] [Abstract][Full Text] [Related]
7. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
Yokota T; Nakamura A; Nagata T; Saito T; Kobayashi M; Aoki Y; Echigoya Y; Partridge T; Hoffman EP; Takeda S
Nucleic Acid Ther; 2012 Oct; 22(5):306-15. PubMed ID: 22888777
[TBL] [Abstract][Full Text] [Related]
8. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.
Moulton HM; Moulton JD
Biochim Biophys Acta; 2010 Dec; 1798(12):2296-303. PubMed ID: 20170628
[TBL] [Abstract][Full Text] [Related]
9. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.
Jearawiriyapaisarn N; Moulton HM; Sazani P; Kole R; Willis MS
Cardiovasc Res; 2010 Feb; 85(3):444-53. PubMed ID: 19815563
[TBL] [Abstract][Full Text] [Related]
10. Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides.
Tone Y; Mamchaoui K; Tsoumpra MK; Hashimoto Y; Terada R; Maruyama R; Gait MJ; Arzumanov AA; McClorey G; Imamura M; Takeda S; Yokota T; Wood MJA; Mouly V; Aoki Y
Nucleic Acid Ther; 2021 Apr; 31(2):172-181. PubMed ID: 33567244
[TBL] [Abstract][Full Text] [Related]
11. Restoring Dystrophin Expression by Skipping Exons 6 and 8 in Neonatal Dystrophic Dogs.
Shah MNA; Yokota T
Methods Mol Biol; 2023; 2587():107-124. PubMed ID: 36401026
[TBL] [Abstract][Full Text] [Related]
12. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
Malerba A; Thorogood FC; Dickson G; Graham IR
Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
14. Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy.
Lim KRQ; Woo S; Melo D; Huang Y; Dzierlega K; Shah MNA; Aslesh T; Roshmi RR; Echigoya Y; Maruyama R; Moulton HM; Yokota T
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35193974
[TBL] [Abstract][Full Text] [Related]
15. Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy.
Miskew Nichols B; Aoki Y; Kuraoka M; Lee JJ; Takeda S; Yokota T
J Vis Exp; 2016 May; (111):. PubMed ID: 27285612
[TBL] [Abstract][Full Text] [Related]
16. Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.
Blain AM; Greally E; McClorey G; Manzano R; Betts CA; Godfrey C; O'Donovan L; Coursindel T; Gait MJ; Wood MJ; MacGowan GA; Straub VW
PLoS One; 2018; 13(6):e0198897. PubMed ID: 29912990
[TBL] [Abstract][Full Text] [Related]
17. Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino.
Wu B; Lu P; Cloer C; Shaban M; Grewal S; Milazi S; Shah SN; Moulton HM; Lu QL
Am J Pathol; 2012 Aug; 181(2):392-400. PubMed ID: 22683468
[TBL] [Abstract][Full Text] [Related]
18. Systemic Injection of Peptide-PMOs into Humanized DMD Mice and Evaluation by RT-PCR and ELISA.
Melo D; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():263-273. PubMed ID: 30171547
[TBL] [Abstract][Full Text] [Related]
19. Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient.
Saito T; Nakamura A; Aoki Y; Yokota T; Okada T; Osawa M; Takeda S
PLoS One; 2010 Aug; 5(8):e12239. PubMed ID: 20805873
[TBL] [Abstract][Full Text] [Related]
20. Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases.
Tsoumpra MK; Fukumoto S; Matsumoto T; Takeda S; Wood MJA; Aoki Y
EBioMedicine; 2019 Jul; 45():630-645. PubMed ID: 31257147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
